GLSI vs. BCYC, CTMX, RGNX, MNPR, PRTA, ETON, GOSS, CRVS, ARCT, and ESPR
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Bicycle Therapeutics (BCYC), CytomX Therapeutics (CTMX), REGENXBIO (RGNX), Monopar Therapeutics (MNPR), Prothena (PRTA), Eton Pharmaceuticals (ETON), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), Arcturus Therapeutics (ARCT), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.
Greenwich LifeSciences vs. Its Competitors
Greenwich LifeSciences (NASDAQ:GLSI) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.
Greenwich LifeSciences presently has a consensus price target of $42.00, suggesting a potential upside of 342.57%. Bicycle Therapeutics has a consensus price target of $22.22, suggesting a potential upside of 172.00%. Given Greenwich LifeSciences' higher probable upside, research analysts clearly believe Greenwich LifeSciences is more favorable than Bicycle Therapeutics.
Greenwich LifeSciences has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
Greenwich LifeSciences has higher earnings, but lower revenue than Bicycle Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Greenwich LifeSciences has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -1,257.00%. Bicycle Therapeutics' return on equity of -32.43% beat Greenwich LifeSciences' return on equity.
4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 51.7% of Greenwich LifeSciences shares are held by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Bicycle Therapeutics had 5 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 7 mentions for Bicycle Therapeutics and 2 mentions for Greenwich LifeSciences. Bicycle Therapeutics' average media sentiment score of 0.54 beat Greenwich LifeSciences' score of 0.30 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.
Summary
Bicycle Therapeutics beats Greenwich LifeSciences on 9 of the 15 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:GLSI) was last updated on 10/19/2025 by MarketBeat.com Staff
Free GLSI Stock Alerts